323 related articles for article (PubMed ID: 31222627)
21. SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML.
DiNardo CD; Stein EM
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):769-772. PubMed ID: 30416011
[TBL] [Abstract][Full Text] [Related]
22. Experimental drugs in clinical trials for acute myeloid leukemia: innovations, trends, and opportunities.
Gołos A; Góra-Tybor J; Robak T
Expert Opin Investig Drugs; 2023 Jan; 32(1):53-67. PubMed ID: 36669827
[TBL] [Abstract][Full Text] [Related]
23. The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia.
Fathi AT; Chen YB
Eur J Haematol; 2017 Apr; 98(4):330-336. PubMed ID: 28000291
[TBL] [Abstract][Full Text] [Related]
24. Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in
Shih AH; Meydan C; Shank K; Garrett-Bakelman FE; Ward PS; Intlekofer AM; Nazir A; Stein EM; Knapp K; Glass J; Travins J; Straley K; Gliser C; Mason CE; Yen K; Thompson CB; Melnick A; Levine RL
Cancer Discov; 2017 May; 7(5):494-505. PubMed ID: 28193779
[TBL] [Abstract][Full Text] [Related]
25. FLT3 Inhibitors for Treating Acute Myeloid Leukemia.
Hassanein M; Almahayni MH; Ahmed SO; Gaballa S; El Fakih R
Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):543-549. PubMed ID: 27450971
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment.
Ghiaur G; Levis M
Hematol Oncol Clin North Am; 2017 Aug; 31(4):681-692. PubMed ID: 28673395
[TBL] [Abstract][Full Text] [Related]
27. FLT3 inhibitors for acute myeloid leukemia.
Lancet JE
Clin Adv Hematol Oncol; 2015 Sep; 13(9):573-5. PubMed ID: 26452187
[No Abstract] [Full Text] [Related]
28. Molecular pathogenesis of AML: translating insights to the clinic.
Levine RL
Best Pract Res Clin Haematol; 2013 Sep; 26(3):245-8. PubMed ID: 24309525
[TBL] [Abstract][Full Text] [Related]
29. Novel Therapeutics in Acute Myeloid Leukemia.
DiNardo CD; Stone RM; Medeiros BC
Am Soc Clin Oncol Educ Book; 2017; 37():495-503. PubMed ID: 28561688
[TBL] [Abstract][Full Text] [Related]
30. Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation.
Best-Aguilera C; Rodrigo Gómez-Vázquez O; Elizabeth Guzmán-Hernández A; Monserrat Rojas-Sotelo R
Curr Oncol Rep; 2017 Mar; 19(3):21. PubMed ID: 28283965
[TBL] [Abstract][Full Text] [Related]
31. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
32. ASP2215 in the treatment of relapsed/refractory acute myeloid leukemia with FLT3 mutation: background and design of the ADMIRAL trial.
Gorcea CM; Burthem J; Tholouli E
Future Oncol; 2018 Aug; 14(20):1995-2004. PubMed ID: 29498296
[TBL] [Abstract][Full Text] [Related]
33. The rocky road to personalized medicine in acute myeloid leukaemia.
Brinda B; Khan I; Parkin B; Konig H
J Cell Mol Med; 2018 Mar; 22(3):1411-1427. PubMed ID: 29327808
[TBL] [Abstract][Full Text] [Related]
34. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
[TBL] [Abstract][Full Text] [Related]
35. T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia.
Alachkar H; Mutonga M; Malnassy G; Park JH; Fulton N; Woods A; Meng L; Kline J; Raca G; Odenike O; Takamatsu N; Miyamoto T; Matsuo Y; Stock W; Nakamura Y
Oncotarget; 2015 Oct; 6(32):33410-25. PubMed ID: 26450903
[TBL] [Abstract][Full Text] [Related]
36. <Editors' Choice> How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement.
Naoe T
Nagoya J Med Sci; 2020 May; 82(2):151-160. PubMed ID: 32581396
[TBL] [Abstract][Full Text] [Related]
37. Targeted Therapeutic Approach Based on Understanding of Aberrant Molecular Pathways Leading to Leukemic Proliferation in Patients with Acute Myeloid Leukemia.
Song MK; Park BB; Uhm JE
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071627
[TBL] [Abstract][Full Text] [Related]
38. FLT3 inhibitors for the treatment of acute myeloid leukemia.
Wiernik PH
Clin Adv Hematol Oncol; 2010 Jun; 8(6):429-36, 444. PubMed ID: 20733555
[TBL] [Abstract][Full Text] [Related]
39. Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?
Fernandez S; Desplat V; Villacreces A; Guitart AV; Milpied N; Pigneux A; Vigon I; Pasquet JM; Dumas PY
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336846
[TBL] [Abstract][Full Text] [Related]
40. Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?
Bewersdorf JP; Stahl M; Zeidan AM
Leuk Lymphoma; 2019 Jun; 60(6):1354-1369. PubMed ID: 30652518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]